SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-027340
Filing Date
2023-08-09
Accepted
2023-08-09 16:02:02
Documents
68
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 924821
2 ex31-1.htm EX-31.1 11918
3 ex31-2.htm EX-31.2 11755
4 ex32-1.htm EX-32.1 8526
5 image_001.jpg GRAPHIC 7891
  Complete submission text file 0001493152-23-027340.txt   4544419

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE mtnb-20230630.xsd EX-101.SCH 36381
7 XBRL CALCULATION FILE mtnb-20230630_cal.xml EX-101.CAL 50955
8 XBRL DEFINITION FILE mtnb-20230630_def.xml EX-101.DEF 88286
9 XBRL LABEL FILE mtnb-20230630_lab.xml EX-101.LAB 266920
10 XBRL PRESENTATION FILE mtnb-20230630_pre.xml EX-101.PRE 209096
62 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 709134
Mailing Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921
Business Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921 908-484-8805
Matinas BioPharma Holdings, Inc. (Filer) CIK: 0001582554 (see all company filings)

IRS No.: 463011414 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38022 | Film No.: 231154991
SIC: 2834 Pharmaceutical Preparations